Key Highlights

● DexCom shares fell 1.9% to close at $86.04 on October 16.

● The consensus 12-month price target is $96.46, implying about 12.1% upside.

● Analysts are split 26 Buy, 3 Hold, and 0 Sell on the stock.

● Targets range from $79 to $115 across 29 analysts.

DexCom, Inc. (NASDAQ:DXCM) closed at $86.04 on October 16, 2026 and is a constituent of the S&P 500. According to market data, the consensus 12-month price target from 29 analysts is $96.46, which implies potential upside of about 12.1% from the latest close. The shares fell 1.90% on Friday after rising earlier in the week on the publication of the CONNECT trial in the New England Journal of Medicine. Analyst targets are forecasts, not guarantees.

What Is the Latest Analyst Price Target?

The mean analyst target is $96.46, with a median of $95 and a range from $79 to $115. At the latest close of $86.04, the consensus target suggests upside of about 12.1%, while the highest target implies 33.7% and the lowest implies -8.2%. The figures reflect data as of October 16, 2026 and may differ from other providers, which use different analyst samples and update schedules. The low target of $79 is about 8% below the price, while the high of $115 is about 34% above it. Only three of 29 analysts rate the stock Hold and none Sell.

What Are Analysts Saying?

The rating split is 26 Buy (22 Strong Buy, 4 Buy), 3 Hold, 0 Sell, giving a consensus rating of Strong Buy. Recent actions reported include the following: Wells Fargo (Larry Biegelsen) maintained Buy at $90 and Citi (Joanne Wuensch) maintained Buy at $105 on October 15, 2026; Mizuho Securities (Anthony Petrone) reiterated Buy and raised its target from $95 to $100 on 13 October; BTIG (Marie Thibault) raised from $90 to $96 on 12 October; and Barclays (Christopher Pasquale) initiated at Buy with a $115 target on 7 October. Individual notes may differ in timing from other sources.

What Could Help the Stock Reach the Price Target?

Trailing twelve-month revenue was $4.97 billion, up 15.5%, with net income of $999.7 million, up 74.9%. Research suggesting glucose monitoring benefits patients with type 2 diabetes who are not on insulin could widen the addressable market, and guidance has been described as 10%+ growth. Analysts noted raised second-quarter guidance and strong execution. If the consensus proves accurate, delivery against these drivers would be needed to close the gap between the share price and the average target.

What Could Prevent the Stock Reaching the Target?

Reimbursement changes, competition in continuous glucose monitoring, and any slowdown in new-patient adoption could weigh on growth. The share price is close to the lower end of the target range, and the stock has been volatile around news. Because targets are opinions about the next twelve months, they can be revised quickly as conditions change.

What Should Investors Watch Next?

DexCom reports third-quarter 2026 results after the market close on October 29, 2026, with a call at 4:30 p.m. Eastern Time. Investors may watch growth, margins and updated guidance.

Betting on the Catch-Up

The consensus target of $96.46 suggests 12.1% upside from $86.04, but it is an aggregate of individual forecasts that rely on assumptions about earnings, valuation and the wider market.